重组人甲状旁腺激素治疗绝经后骨质疏松妇女临床研究

目的观察重组人甲状旁腺激素治疗绝经后骨质疏松妇女的临床疗效。方法选择绝经后妇女骨质疏松患者58例随机分为观察组31例和对照组27例,观察组给予皮下注射重组人甲状旁腺素20ug每天1次;对照组给予肌肉注射降钙素20IU每1次,两组均每日给予钙尔奇D600mg/d,连续治疗6个月。观察两组腰椎(L2～L4)的骨密度及T值,血钙磷及碱性磷酸酶(AKP)等指标的变化情况及不良反应。结果治疗后观察组和对照组腰椎(L2～L4)的骨密度均有明显的增加(P<0.01)。但两组间比较无明显差异。观察组治疗后的碱性磷酸酶明显增高,而对照组无明显变化。对照组治疗后的血清胆固醇降低显著优于观察组(P<0.01)。两组均未发生严重不良反应。结论重组人甲状旁腺激素与降钙素都能显著提高骨密度(BMD)和缓解骨质疏松的症状,对于治疗绝经后的骨质疏松安全有效。

Objective Recombinant human parathyroid hormone therapy in postmenopausal women with osteoporosis clinical efficacy. Methods Postmenopausal women with osteoporosis in 58 patients randomly divided into 31 patients and a control group of 27 cases observed were given subcutaneous injection of recombinant human parathyroid hormone 20ug day 1; control group received intramuscular calcitonin 20IU per 1, two groups were given daily Caltrate D 600 mg / d, continuous treatment for 6 months. Were observed in lumbar spine （L2 - L4） bone mineral density and T values, blood calcium and phosphorus, and alkaline phosphatase and other indicators of changes and adverse reactions. Results After treatment, observation and control groups lumbar （L2 - L4） bone mineral density were significantly increased （P〈0.01）. However, no significant difference between the two groups. After treatment of the alkaline phosphatase was significantly higher in the control group no significant change. Control group after treatment of serum cholesterol was significantly better than the observation group （P〈0.01）. Both groups no serious adverse reactions. Conclusion Recombinant human parathyroid hormone and calcitonin can significantly improve bone density and relieve the symptoms of osteoporosis for postmenopausal osteoporosis treatment safe and effective.